ENLIVEN THERAPEUTICS INC.
NASDAQ: ELVN (Enliven Therapeutics, Inc.)
Kemas kini terakhir: semalam, 6:50AM49.82
1.06 (2.17%)
| Penutupan Terdahulu | 48.76 |
| Buka | 48.76 |
| Jumlah Dagangan | 844,241 |
| Purata Dagangan (3B) | 1,378,808 |
| Modal Pasaran | 3,559,055,104 |
| Harga / Buku (P/B) | 7.68 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.92 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.23% |
| Nisbah Semasa (MRQ) | 21.07 |
| Aliran Tunai Operasi (OCF TTM) | -73.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -45.43 M |
| Pulangan Atas Aset (ROA TTM) | -21.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Menaik |
| Biotechnology (Global) | Menaik | Menaik | |
| Stok | Enliven Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.50 |
|
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 4.75% |
| % Dimiliki oleh Institusi | 90.86% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Commodore Capital Lp | 31 Mar 2026 | 3,275,000 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | - | 45.96 | -860,123 | -39,531,253 |
| Jumlah Keseluruhan Kuantiti Bersih | -860,123 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -39,531,253 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 45.96 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 22 Jun 2026 | Jual (-) | 860,123 | 45.96 | 39,531,253 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |